From December 3rd to 5th, 2024, Yoram Bouhnik had the privilege to represent the Institut des MICI – Paris IBD Center, part of the Groupe Hospitalier Privé Ambroise Paré – Hartmann as a guest of Dr. David T. Rubin and his outstanding team.
This recognition highlights the incredible work we’ve achieved at the Paris IBD Center, integrating personalized care, precision medicine, and innovative research.
During this program, Yoram Bouhnik shared insights from our key initiatives:
Contributions to IBD clinical research with the GETAID including:
- The SECURITY study, led by Xavier Treton evaluating the impact of remote monitoring (via the SÊMEIA application) on symptomatic remission in patients with active IBD.
- The CREDO study, aimed at developing and validating a novel score for endoscopic remission in IBD, advancing the precision of disease activity evaluation.
Our holistic approach, in collaboration with the Institut Rafaël Santé Intégrative and with the support of the Afa Crohn RCH France. This partnership underpins the upcoming HOLI-MICI study, focused on evaluating multimodal care to improve the quality of life for IBD patients.
Our precision medicine initiative, developed in partnership with Ariana Pharma as part of the IBD-Drive project, leveraging explainable AI to advance biomarker discovery and optimize therapeutic strategies for IBD management.
Discussions on improving patient recruitment strategies for clinical trials, with a close ongoing collaboration with Iterative Health, focused on refining approaches to enhance participation and efficiency in IBD studies.
This exchange was an incredible opportunity to strengthen ties with University of Chicago IBD Center and the global gastroenterology community, bringing together physicians, researchers, and engineers.
One of the highlights was the Research Review with all members of the Rubin Lab, where we explored cutting-edge projects aimed at improving patient care and quality of life for those living with IBD.
A heartfelt thank you to Dr. David T Rubin, Dr. Russell D. Cohen, and the entire University of Chicago team for their warm welcome and inspiring discussions.
Together, we continue to shape the future of IBD treatment and care!
